Not every cancer patient is the same.
The premier solution for measuring variability in disease experience and the impact of new cancer therapies in the real world.
Why Oncology Leaders Choose Folia
Solve common RWD challenges with a better dataset, Home Reported Outcomes:
Measure disease heterogeneity and phenotypes
Analyze acute events, exacerbations, and side effects in real-time, outside of the clinic setting
Understand self-reported treatment use and behaviors: “Why not?” reasons for missing doses/switching medications
Patient-driven, high fidelity, and high value insights:
Comprehensive outcomes/symptoms analysis versus restricted PRO measurements
Responder burden, survey fatigue, and recall bias are greatly reduced
Value to the patient: patients can utilize their own data for care decisions
On a mission to bridge the subjective experience of individuals
with high-quality, research-grade outcomes data.
This gives you insight that you don’t get from PROs and does not rely on long recall period. To me, that is the interesting nuance
Executive Director, WW HEOR RWD (Top 10 Pharma)
Featured Blog Posts
